<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03850834</url>
  </required_header>
  <id_info>
    <org_study_id>AMXT201802/PRO</org_study_id>
    <nct_id>NCT03850834</nct_id>
  </id_info>
  <brief_title>Study of Ammoxetine Hydrochloride Enteric-coated Tablets in Healthy Subject</brief_title>
  <official_title>A Multiple-dose Study to Evaluate the Tolerability and Pharmacokinetics of Ammoxetine Hydrochloride Enteric-coated Tablets in Chinese Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety, tolerability and pharmacokinetics of Ammoxetine
      Hydrochloride Enteric-coated Tablets in Chinese healthy subjects
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 10, 2019</start_date>
  <completion_date type="Anticipated">October 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Event</measure>
    <time_frame>15 days</time_frame>
    <description>Incidence of Adverse Events that researchers determined clinical significance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the plasma concentration time curve (AUC)</measure>
    <time_frame>11 days</time_frame>
    <description>The pharmacokinetics(PK) profile of Ammoxetine Hydrochloride Enteric-coated Tablets</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum concentration (Cmax)</measure>
    <time_frame>11 days</time_frame>
    <description>The pharmacokinetics(PK) profile of Ammoxetine Hydrochloride Enteric-coated Tablets</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half life Period (t1/2)</measure>
    <time_frame>11 days</time_frame>
    <description>The pharmacokinetics(PK) profile of Ammoxetine Hydrochloride Enteric-coated Tablets</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Ammoxetine Hydrochloride Enteric-coated Tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Enteric-coated Tablets</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ammoxetine Hydrochloride Enteric-coated Tablets</intervention_name>
    <description>There will be 3 ascending cohorts. The cohorts will be administered 15, 30, 45 mg q12h for 15 times. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested</description>
    <arm_group_label>Ammoxetine Hydrochloride Enteric-coated Tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo enteric-coated tablets</intervention_name>
    <description>There will be 3 ascending cohorts. The cohorts will be administered 15, 30, 45 mg q12h for 15 times. The results of each dose group were shown to be safe and tolerable, and then the next dose group was tested</description>
    <arm_group_label>Placebo Enteric-coated Tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females age 18-45 years

          -  Body weight ≥ 45kg (female) or 50Kg (male), 18 ≤ BMI ≤ 26

          -  Vital signs, physical examinations and laboratory tests and other tests prove
             participants are healthy

          -  Sign the informed consent form voluntarily and cooperate voluntarily to complete the
             test

        Exclusion Criteria:

          -  Allergens (allergic to 2 or more drugs, food or pollen)

          -  comorbid illness (mental illness, liver and kidney disease, gastrointestinal diseases,
             nervous system disease, or other systemic diseases)

          -  have Clinically significant abnormal screening laboratory values.

          -  Systolic pressure &gt; 140mmHg or diastolic &gt; 90 mmHg

          -  Postural hypotension (systolic blood pressure drop by 20mmHg or diastolic blood
             pressure drop by 10mmHg after standing position)

          -  The QTc period ≥ 450ms (male) or 470ms (female) or has a history of QTc extension

          -  Smoking or alcohol consumption (14 units per week in the previous 4 weeks : 1 unit =
             beer 285mL, or 25mL of spirits, or 150 mL of wine; Daily smoking ≥ 5) or abusing in
             past year of drug and other substance

          -  Have donated or lost blood 400 ml within 8 weeks prior to screening

          -  Participated in other clinical trials within 3 months prior to screening

          -  Intakes too much caffeinated beverage or food within 4 weeks prior to screening. such
             as: Coffee, tea, chocolate, cola, red bull (no more than 6 units per day). 1 unit of
             caffeine = 1 cup of coffee (177.4 mL) = 2 pots of cola (354.9 mL) = 1 cup of tea
             (354.9 mL) = 1/2 cup energy drink = 85g chocolate

          -  Have taken drugs that changed liver enzyme activity, such as dexamethasone,
             ketoconazole, rifampicin and omeprazole, were used within 4 weeks prior to screening

          -  Have taken prescription drugs and OTC (except for the occasional use of acetaminophen
             and nasal sprays), herbs vitamins or minerals within 4 weeks prior to screening. The
             interval from prior treatment to screening should be at least 5 half-lives metablism
             which subjected to the longer halflife

          -  Using any psychotropic drug or psychoactive substance

          -  Women were screened for positive blood pregnancy

          -  The subjects and their partners were not willing to take contraceptives during trial
             and six months after the study

          -  Have a donor plan recently

          -  Have participated in this trial

          -  The researchers believe that anyone who is unfit to participate in this test will be
             involved
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 20, 2019</study_first_submitted>
  <study_first_submitted_qc>February 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2019</study_first_posted>
  <last_update_submitted>February 20, 2019</last_update_submitted>
  <last_update_submitted_qc>February 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

